Limb-girdle muscular dystrophy
Log in to starLast updated Nov 3, 2026
A young adult presents with progressive proximal weakness affecting hips and shoulders. CK is elevated. Genetic testing reveals a variant in a sarcoglycan gene.
Heterogeneous (>30 subtypes); the genes encode different muscle proteins, so the mechanism differs by subtype.
- AD (LGMD D): rare; includes dominantly acting CAPN3 variants
- AR (LGMD R): more common; sarcoglycans (SGCA, SGCB, SGCG, SGCD), calpain-3 (CAPN3), dysferlin (DYSF), others
Many genes give one picture, proximal weakness and dystrophic muscle, usually with a high CK, but each acts on a different protein. Three recessive groups can be recognized by staining the biopsy for the missing protein:
- Sarcoglycans: the four proteins form one complex at the muscle membrane that steadies dystrophin's link to the dystroglycans. A variant in any one gene leaves all four deficient on staining, so staining shows a sarcoglycanopathy but not which gene. These are the usual cause of severe childhood-onset weakness that looks like Duchenne with normal dystrophin. Cardiomyopathy is common in beta, gamma, and delta forms and rare in alpha.
- Calpain-3: a muscle-specific, calcium-activated protease that remodels the sarcomere. Most variants are recessive loss of function. A few, such as c.643_663del21, act dominantly, probably because active calpain-3 is a dimer and the abnormal protein pairs with the normal one and inactivates it. In 10% to 30%, a western blot shows normal amounts of a protein that may still be inactive, so a normal blot does not exclude the diagnosis.
- Dysferlin: a membrane protein for calcium-driven membrane repair; loss-of-function variants leave very little at the membrane.
- Proximal weakness (pelvic and shoulder girdle)
- Variable onset and severity by subtype
- Elevated CK
- Some subtypes: cardiomyopathy, respiratory involvement
- Elevated serum CK with proximal weakness prompts evaluation; EMG and muscle MRI support a myopathic pattern
- Multigene LGMD panel (or broad neuromuscular panel) is the preferred confirmatory test given marked locus heterogeneity
- Muscle biopsy with immunohistochemistry (sarcoglycans, dysferlin, dystrophin) when molecular testing is inconclusive
- Physical and occupational therapy to preserve mobility; orthopedic management of contractures and scoliosis
- Cardiac surveillance (ECG, echocardiogram) for subtypes with cardiomyopathy or conduction disease
- Pulmonary function monitoring with respiratory support as needed in subtypes with diaphragmatic involvement
- Multidisciplinary neuromuscular care; genetic counseling reflecting subtype-specific inheritance (AR vs AD)
"LGMD = young adult with progressive weakness in shoulders and hips": Think of LGMD when you see proximal weakness affecting both the pelvic and shoulder girdle (vs Becker, which predominantly affects hips). LGMD is an example of locus heterogeneity (>30 genes cause the same clinical phenotype).